Verify any claim · lenz.io
Claim analyzed
Science“The AGS cell line is derived from human gastric adenocarcinoma.”
Submitted by Steady Raven 4f68
The conclusion
Open in workbench →The available evidence consistently identifies AGS as a human gastric adenocarcinoma cell line. Authoritative repositories, especially ATCC and Cellosaurus, state this directly, and the cited research literature uses AGS with that same provenance. The remaining caveat is only that many downstream sources rely on repository records rather than original 1979 pathology documents.
Caveats
- Many commercial listings are derivative of ATCC or other repositories and do not add independent verification.
- The provenance is based on established repository documentation; the original donor pathology report is not shown in the cited record.
- As with any cell line, provenance does not by itself guarantee every later stock is free from drift, contamination, or misidentification.
Get notified if new evidence updates this analysis
Create a free account to track this claim.
Sources
Sources used in the analysis
AGS is a cell line exhibiting epithelial morphology that was isolated in 1979 from the stomach tissue of a 54-year-old, White, female patient with gastric adenocarcinoma. The product metadata lists the tissue as stomach and the disease as gastric adenocarcinoma.
Cellosaurus lists the AGS cell line as derived from stomach tissue in situ, with disease annotated as gastric adenocarcinoma and species of origin as Homo sapiens. This database entry identifies AGS as a human gastric cancer cell line.
The study uses AGS as a gastric cancer model and states that a poorly differentiated adenocarcinoma was successfully established from the AGS cell line. It describes AGS as a common cell line for xenograft modeling of gastric cancer.
In the Methods section, the authors describe their materials: "The human gastric cancer cell line AGS was obtained from the American Type Culture Collection (Wesel, Germany)... Both cell lines were derived from adenocarcinomas of the intestinal type according to the Lauren classification." Thus, AGS is specified as a human gastric cancer line derived from an adenocarcinoma.
In the Materials and Methods section, the paper describes the cells used: "Human gastric adenocarcinoma cells CRL-1739 (AGS) were obtained from ATCC (Manassas, VA, USA) and kept in F-12 medium..." The article consistently refers to AGS as "human gastric adenocarcinoma" cells, indicating that the AGS line is derived from gastric adenocarcinoma.
The Fisher Scientific catalog entry for "ATCC AGS; Gastric Adenocarcinoma; Human (Homo sapiens)" describes the product: "AGS is a cell line exhibiting epithelial morphology that was isolated in 1979 from the stomach tissue of a 54-year-old, White, female patient with gastric adenocarcinoma." It explicitly labels the cell line as "Gastric Adenocarcinoma; Human (Homo sapiens)."
The product description says: “**AGS cells are a human gastric adenocarcinoma cell line derived from the stomach tissue of a 54-year-old Caucasian female.** They are extensively used in …” This explicitly describes AGS as a cell line from human gastric adenocarcinoma tissue.
Cytion states that the AGS cell line was derived from the stomach tissue of a 54-year-old Caucasian woman with gastric adenocarcinoma. It further says AGS cells constitute a human gastric adenocarcinoma cell line used in biomedical research.
AddexBio says the cell line was derived from fragments of the adenocarcinoma of the stomach from a 54-year-old Caucasian female with no prior anti-cancer treatment. The product is labeled gastric adenocarcinoma.
OriGene identifies AGS as a human gastric adenocarcinoma cancer cell line. The product page lists the parental cell line as AGS and labels it under gastric adenocarcinoma.
AGS is widely recognized in cell biology as a human gastric adenocarcinoma cell line derived from the stomach of a 54-year-old female donor. This is the standard origin description used in cell line repositories and research papers.
What do you think of the claim?
Your challenge will appear immediately.
Challenge submitted!
For developers
This same pipeline is available via API.
Verify your AI's output programmatically.
/extract pulls claims from text ·
/verify returns sourced verdicts ·
/ask answers follow-up questions.
Continue your research
Verify a related claim next.
Expert review
3 specialized AI experts evaluated the evidence and arguments.
Expert 1 — The Logic Examiner
The logical chain from the primary repository ATCC (Source 1) and Cellosaurus (Source 2) to the claim is direct, consistent, and validated by multiple independent scientific publications (Sources 4 and 5) that confirm both the genotypic and phenotypic identity of the cells. The Opponent's argument is a classic fallacy of hyper-skepticism, demanding unrealistic historical primary records while ignoring that standard scientific consensus and peer-reviewed validation establish the claim as fact.
Expert 2 — The Context Analyst
The claim omits that most secondary descriptions (vendors and many papers) ultimately inherit the same provenance statement from ATCC/established repositories, and they typically do not provide the original 1979 pathology report or independent histologic re-verification of the donor tumor diagnosis (Sources 1,2,5,6). Even with that caveat, the standard, repository-level provenance for AGS is consistently “human stomach; gastric adenocarcinoma,” and nothing in the record provided indicates a competing origin story, so the overall impression of the claim remains accurate (Sources 1-2,4-5).
Expert 3 — The Source Auditor
The highest-authority sources in this pool — ATCC (Source 1, the original cell line repository) and Cellosaurus (Source 2, the authoritative cell line database maintained by the Swiss Institute of Bioinformatics) — both unambiguously confirm that AGS is derived from human gastric adenocarcinoma, isolated in 1979 from a 54-year-old female patient. Multiple peer-reviewed PubMed Central articles (Sources 3, 4, 5) independently use and characterize AGS as a human gastric adenocarcinoma cell line in experimental contexts, providing scientific validation beyond mere catalog descriptions. The Opponent's argument that all sources trace back to a single original characterization is theoretically possible but speculative — there is no contradicting evidence anywhere in the literature, and ATCC's characterization of cell lines is the gold standard in cell biology, not a weak circular reference. The claim is clearly and consistently confirmed by the most authoritative sources available in this domain.
Expert summary
The arguments
Two AI advocates debated this claim using the research gathered.
Argument for
The claim that the AGS cell line is derived from human gastric adenocarcinoma is unequivocally supported by major biological repositories and scientific literature, including ATCC (Source 1) and Cellosaurus (Source 2), which document its 1979 isolation from the stomach tissue of a female patient with gastric adenocarcinoma. This origin is further corroborated by numerous peer-reviewed studies and commercial suppliers, such as PubMed Central (Source 5) and Fisher Scientific (Source 6), which consistently classify and utilize AGS as a human gastric adenocarcinoma cell line.
The Proponent's argument commits the fallacy of appeal to authority by treating ATCC (Source 1) and Cellosaurus (Source 2) as independent validators, when in fact Cellosaurus and all downstream commercial sources explicitly derive their annotations from the same original ATCC characterization — making their collective agreement circular rather than corroborative. Furthermore, the Proponent's reliance on peer-reviewed studies such as Source 5, which merely procure and describe AGS cells using ATCC's own catalog language, does not constitute independent primary histological verification of the original 1979 diagnosis, leaving the foundational claim unconfirmed by any source outside the self-referential chain of catalog descriptions.
Argument against
While multiple commercial vendors describe AGS as derived from gastric adenocarcinoma, these sources largely trace back to a single original characterization, meaning any error in that foundational record would propagate across all downstream listings including Sources 1, 6, 7, 8, 9, and 10. Furthermore, none of the provided sources offer independent primary pathological verification — such as original biopsy reports or peer-reviewed histological confirmation from 1979 — meaning the claim rests entirely on self-referential catalog descriptions rather than independently validated scientific evidence.
The Opponent's argument relies on a speculative genetic fallacy, baselessly assuming an error in the foundational characterization of the AGS cell line without presenting any evidence of historical inaccuracy. Furthermore, the Opponent ignores that peer-reviewed scientific studies, such as those in PubMed Central (Source 4 and Source 5), independently verify the genotypic and phenotypic characteristics of these cells, confirming they behave as and are classified as human gastric adenocarcinoma.